Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Continuous evolution of Omicron has led to a rapid and simultaneous emergence of
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …

Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …

Background SARS-CoV-2 vaccines currently authorized for emergency use have been
highly successful in preventing infection and lessening disease severity. The vaccines …

Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …

Multiple BA. 4 and BA. 5 subvariants with Arg346 mutations in the spike glycoprotein have
been identified in various countries, such as BA. 4.6, BF. 7, BA. 5.2. 6, BA. 4.1. 9, and BE. 1.2 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic. Antibody resistance dampens neutralizing antibody therapy and threatens …

Over the last three years, the pandemic of COVID-19 has had a significant impact on
people's lives and the global economy. The incessant emergence of variant strains has …

Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …